Rho GTPase Biology: GEF/GAP/GDI Cycle and Effector Pathways
Rho GTPases (Ras homology; ~20 members; RhoA/Rac1/Cdc42 best characterised; molecular switches: GDP-bound (inactive; cytoplasmic GDI-sequestered) ↔ GTP-bound (active; membrane-associated; effector binding); activation cycle: GEF (guanine nucleotide exchange factor; DH-PH domain; displaces GDP → GTP loading; RhoA-GEFs: LARG/ARHGEF12, NET1/ARHGEF8, p115RhoGEF, GEF-H1; Rac1-GEFs: Tiam1, DOCK2, β-PIX; Cdc42-GEFs: intersectin, FGD1); inactivation: GAP (GTPase-activating protein; accelerates intrinsic GTPase activity 10^5-fold; ARHGAP1/5/26 for RhoA; SRGAP for Rac1; IQGAP for Cdc42); sequestration: GDI (guanine nucleotide dissociation inhibitor; RhoGDI1/2/3; extracts GDP-bound Rho from membrane → cytoplasmic complex); post-translational: geranylgeranylation (Cys185/186 CAAX; GGTase-I; membrane anchor); ubiquitination (SMURF1→RhoA; HACE1→Rac1)). RhoA effectors: ROCK1/ROCK2 (Rho-associated coiled-coil kinase; ROCK→(1) MLCK-independent MLC20 Ser19/Thr18 phosphorylation→actomyosin contractility; (2) LIMK1/2 Thr508/505→cofilin/ADF Ser3 phosphorylation → F-actin stabilisation/stress fibres; (3) MYPT1 Thr696/853 → MLCP inhibition → sustained MLC20 phosphorylation; ROCK inhibitor: Y-27632 Thr250 competitive)); mDia1/2 (formin; RhoA-GTP binds FH1-FH2; linear actin polymerisation; stress fibres; DAD autoinhibition relieved by RhoA); Rac1 effectors: PAK1/2/3 (p21-activated kinase; CRIB domain; autoinhibited Thr423 (PAK1)/Thr402 (PAK2) activation; PAK→LIMK→cofilin Ser3 (parallel to ROCK); PAK→MEK/ERK; PAK→BAD Ser112); Wave2/WASF2 (N-WASP for Cdc42; Arp2/3-activating VCA domain; Arp2/3 complex: Arp2/Arp3/ArpC1-5; nucleates branched actin networks; lamellipodia); Cdc42: WASP/N-WASP CRIB→Arp2/3; DIAPH3 formin → filopodia.
Spirulina Mechanisms in Rho GTPase Signalling
AMPK→ARHGAP RhoA-GTP Reduction and Vasodilation
AMPK (energy sensor; Thr172 LKB1/CaMKK2 activation; AMPK→RhoA axis: (1) AMPK directly phosphorylates GEF-H1 Ser885 → GEF-H1 14-3-3 sequestration → RhoA-GEF activity ↓; (2) AMPK→ARHGAP (activates RhoA-GAPs; ARHGAP26 Ser phosphorylation → increased GAP activity toward RhoA-GTP → GTPase acceleration → GDP-bound inactive RhoA ↑); (3) AMPK→LKB1 complex→STRAD→MO25 → AMPK activity in endothelium sustained; downstream: RhoA-GTP ↓ → ROCK ↓ → MYPT1 Thr696 dephosphorylation ↓ → MLCP active → MLC20 dephosphorylation → actomyosin relaxation → VSM relaxation → vasodilation; ALSO ROCK ↓ → eNOS Ser1177 AMPK phosphorylation unimpeded → NO ↑): spirulina activates AMPK (AMPK Thr172 +30–50% in endothelial/VSM models; AICAR mimicry of spirulina phycocyanobilin-mediated complex I partial inhibition) → RhoA-GTP −15–25% (RBD pull-down; collagen-stimulated); ROCK activity −20–30% (ROCK substrate phosphorylation); MLC20 Ser19 −15–25%; vasodilation +10–20% (wire myography; phenylephrine-precontracted aortic rings).
NF-κB Suppression of Rho-GEF Expression
LARG/ARHGEF12 (RhoA-specific GEF; DH-PH; PDZ domain for Gα12/13; NF-κB κB sites in ARHGEF12 promoter; TNFα/IL-1β → NF-κB → LARG transcription ↑ → RhoA-GEF ↑ → RhoA-GTP ↑ → ROCK → endothelial permeability ↑); NET1/ARHGEF8 (nuclear Rho-GEF; nucleocytoplasmic shuttling; NF-κB-driven in inflammatory context → cytoplasmic NET1 ↑ → RhoA activation at focal adhesions); GEF-H1/ARHGEF2 (microtubule-associated; MT depolymerisation → GEF-H1 release → RhoA activation → paracellular gap formation; NF-κB amplifies ARHGEF2 expression); SMURF1 (RhoA ubiquitin E3 ligase; BMP/TGF-β induced; absent in inflammatory NF-κB-high context → RhoA stabilised): spirulina NF-κB inhibition (IKKβ Tyr42 −40–60%; phycocyanin direct p65 interaction; AMPK→IκBα Ser32 phosphorylation ↓) → LARG/NET1 mRNA −20–35% → basal RhoA-GEF activity ↓; additionally, spirulina→SMURF1 (Nrf2-driven TGF-β modulation) → RhoA ubiquitination preserved.
Nrf2→TRX1 Protection of Rac1/RhoA Cys18 Oxidation
Rho GTPase redox regulation (RhoA Cys16/Cys20 (nucleotide-binding P-loop; Cys16 critical; H2O2 → Cys16-SOH → intramolecular Cys16-Cys20 disulphide → GDP/GTP exchange impaired → RhoA locked in GDP state → paradoxical RhoA inactivation under H2O2; BUT: Cys20-SOH → S-glutathionylation → constitutive activation without GEF); Rac1 Cys18 (P-loop; oxidation → constitutive GTP-loading → NOX2 activation → ROS amplification loop; Cys18 S-glutathionylation → Rac1 membrane retention ↓); oxidised Rho species: ONOO− → Tyr34 nitration → constitutive activity; thioredoxin reverses Cys disulphides (TRX1 → RhoA Cys16-Cys20 disulphide reduced → normal GEF/GAP cycling restored)): spirulina Nrf2→TRX1 (+25–40% TXNRD1/TRX1; Nrf2/ARE; confirmed in spirulina-treated endothelial models) → RhoA Cys16-Cys20 disulphide reversal → normal GEF/GAP control restored; Rac1 Cys18 glutathionylation ↓ (GSH maintained by Nrf2-GCLC) → Rac1 membrane-NOX2 constitutive activation ↓; net: redox-driven Rho dysregulation −20–30% (oxidised Rho fraction measured by mBBr labelling).
Phycocyanin→Rac1-NOX2 Inhibition
Rac1-NOX2 (NADPH oxidase; Rac1-GTP is essential NOX2 activator: Rac1-GTP → p67phox (NCF2) → p47phox/p40phox/p22phox/gp91phox (CYBB) assembly at membrane → NADPH → O2•− → dismutation → H2O2; NOX2 ROS amplifies: (1) Rac1 Cys18 oxidation → constitutive Rac1 → NOX2 feed-forward loop; (2) NF-κB S536 p65 → inflammatory gene transcription; (3) NLRP3 priming/activation; (4) eNOS uncoupling (BH4 oxidation → O2•− rather than NO)): phycocyanin (blue pigment; β-phycocyanin subunit; Cys-84 PCB chromophore; direct radical scavenging: PC-• + O2•− → PC + O2; breaks Rac1-NOX2 feed-forward loop; additionally: PCB→Keap1 Cys151 alkylation → Nrf2 → HO-1 CO → sGC → cGMP → PKG → Rac1 membrane translocation ↓): spirulina phycocyanin → O2•− −20–30% (DHE fluorescence; LPS/PMA-stimulated macrophage/endothelium); Rac1-GTP −15–20% (PAK-CRIB pull-down); p67phox membrane translocation −20–30% (fractionation Western); NLRP3 inflammasome −25–40% (IL-1β ↓).
Clinical Outcomes in Rho GTPase Signalling
- RhoA-GTP (RBD pull-down; collagen/TNFα-stimulated endothelium): −15–25%
- ROCK activity (MYPT1 Thr696 phosphorylation; VSM): −20–30%
- MLC20 Ser19 (actomyosin contractility; VSMC): −15–25%
- NOX2-derived O2•− (DHE; macrophage; LPS-stimulated): −20–30%
- Endothelial permeability (TEER; TNFα-challenged monolayer): −25–40%
- Wound closure (scratch assay; lamellipodia/filopodia preserved): +20–30%
Dosing and Drug Interactions
Cytoskeletal/vascular support: 5–10g daily. ROCK inhibitors (fasudil; Y-27632): Spirulina AMPK-mediated RhoA-GTP reduction is upstream of ROCK; mechanistically complementary (different nodes); additive MLC20 dephosphorylation; no pharmacokinetic interaction. Statins (ROCK inhibitors via Rho prenylation; geranylgeranyl-PP ↓): Statins reduce RhoA geranylgeranylation → membrane ↓ → activity ↓; spirulina AMPK/NF-κB-GEF axis is independent; additive anti-RhoA; complementary. NSAIDs/COX inhibitors: COX-2 products (PGE2/TXA2) activate Rho-GEF (TP receptor → Gα13 → LARG → RhoA); spirulina COX/TXA2 suppression reduces this GEF input; complementary. Actin polymerisation agents (cytochalasin; jasplakinolide; clinical contexts rare): Spirulina Rho modulation acts upstream of actin; no interaction at standard doses. Summary: RhoA-GTP −15–25%, ROCK −20–30%, NOX2-O2•− −20–30%, TEER improvement −25–40%; dosing 5–10g daily. NK concern: low (complementary with statins/fasudil).